The innovation described in this proposal is aimed at providing a new method for characterization of lot-to-lot consistency of microheterogeneous recombinant products. The biological effect and potency of a drug is governed by the chemical structure for both traditional drugs and biopharmaceuticals. Standard analytical techniques are either inadequate for complete characterization of protein-based products or too costly and complex. This SBIR proposal is targeted at difficult quality control problems associated with microheterogeneity of widely available recombinant glycoproteins. ANALIZA is proposing to develop and validate a physicochemical test that is unique (in regard to the type of information obtained), quantitative, inexpensive (relative to present methodologies), flexible (in that it may be used for different biologicals), easy to perform and labor-efficient. The technique provides a unique and highly sensitive information on minor changes in the structure and conformation of the glycoprotein product related to its potency. Phase I research effort is designed to demonstrate feasibility of the suggested technique as a QA/QC test by developing and validating the proposed analytical methodology for analysis of a biopharmaceutical product to be determined with biopharmaceutical collaborators.
A new analytical technology that improves the control of safety and efficacy of glycoprotein-based drugs offers significant benefits given the increasing use and variety of such products on the market. The proposed method may reduce manufacturing costs and effort, while increasing safety and efficacy control of the products by providing a rapid, simple, and sensitive test for QC/QA monitoring of recombinant and other biological glycoprotein-based products.
